Compugen (NASDAQ:CGEN – Get Free Report) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01), FiscalAI reports. Compugen had a net margin of 48.57% and a return on equity of 55.68%. The firm had revenue of $2.18 million during the quarter, compared to analyst estimates of $1.57 million.
Compugen Stock Performance
NASDAQ:CGEN opened at $2.75 on Monday. The stock has a fifty day moving average price of $2.49 and a 200-day moving average price of $1.99. The company has a market cap of $260.01 million, a price-to-earnings ratio of 7.43 and a beta of 2.79. Compugen has a fifty-two week low of $1.29 and a fifty-two week high of $3.23.
Institutional Trading of Compugen
A number of institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its position in shares of Compugen by 3.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,456,900 shares of the biotechnology company’s stock valued at $2,229,000 after acquiring an additional 51,565 shares during the period. State Street Corp lifted its position in shares of Compugen by 3.9% during the 4th quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock worth $603,000 after buying an additional 14,701 shares during the last quarter. Jane Street Group LLC lifted its position in shares of Compugen by 1,077.0% during the 2nd quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock worth $700,000 after buying an additional 359,785 shares during the last quarter. Two Sigma Investments LP boosted its stake in Compugen by 10.6% in the third quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock valued at $291,000 after buying an additional 18,929 shares in the last quarter. Finally, Marshall Wace LLP boosted its stake in Compugen by 135.7% in the fourth quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock valued at $163,000 after buying an additional 61,202 shares in the last quarter. 12.22% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Read Our Latest Stock Report on CGEN
About Compugen
Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.
Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.
Recommended Stories
- Five stocks we like better than Compugen
- As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.
